Australian Bioxyne Limited has signed a manufacturing agreement with global medical cannabis company Aurora Cannabis Inc., marking a significant step in its international expansion.

The deal, executed through Bioxyne’s wholly owned subsidiary Breathe Life Sciences (BLS), covers the production of pharmaceutical-grade medicinal cannabis products for supply into key markets.

The initial agreement includes the supply of GMP-certified medicinal cannabis oils into the Australian market, with deliveries already completed. The partnership is also expanding to include GMP-manufactured cannabis vapes for distribution across Australia, the United Kingdom and Germany, with onboarding for additional product lines now underway.

The collaboration reflects Bioxyne’s evolution from a domestic manufacturer to a global supplier capable of meeting the demands of highly regulated pharmaceutical environments. It also reinforces the company’s position in precision-dosed cannabis formats and scalable production.

“This partnership with Aurora represents a significant milestone for BLS as we expand our manufacturing capabilities. We are excited about the potential of our broader product portfolio across multiple international markets. This agreement validates our pharmaceutical manufacturing expertise and positions us well for growth,” said chief executive officer Sam Watson.

Aurora’s executive vice president, operations and supply chain, Alex Miller, said the agreement strengthens the company’s global supply chain. “As a global leader in medical cannabis, we’re focused on building a resilient, high-quality supply chain across key international markets. BLS brings strong GMP-manufacturing capabilities that complement our scale, regulatory scrutiny and commitment to delivering high quality medical cannabis products to patients.”

The companies have agreed to expand the scope of the agreement, including the production and distribution of a large quantity of vape products. Discussions are also progressing around additional product lines for Australia, the UK and Germany, further broadening BLS’s manufacturing footprint and market reach.

Article by Manufacturer’s Monthly: https://www.manmonthly.com.au/bioxyne-partners-with-aurora-cannabis/

Bioxyne Limited has announced a new manufacturing agreement with Aurora Cannabis Inc., placing manufacturing at the center of a partnership aimed at supplying pharmaceutical-grade cannabis products to multiple international markets.

In an ASX statement, Bioxyne Limited said its wholly owned subsidiary, Breathe Life Sciences, will manufacture medicinal cannabis products under Good Manufacturing Practice (GMP) standards as part of the agreement with the Canadian-based producer.

The company stated the initial phase of the manufacturing agreement covers the supply of GMP-certified medicinal cannabis oils to Australia, noting that “initial deliveries [have] already [been] completed.”

The scope is also being expanded to include GMP-manufactured cannabis vape products intended for distribution in Australia, the United Kingdom and Germany.

Bioxyne described the agreement as a step forward in its manufacturing strategy, saying it “underscores [its] growing credibility as a global player in pharmaceutical-grade cannabis manufacturing and its ability to deliver high-quality, scalable solutions.”

Chief Executive Officer Sam Watson said the deal represents a milestone for the company’s manufacturing operations. “This partnership with Aurora represents a significant milestone for BLS as we expand our manufacturing capabilities,” Watson said.

“We are excited about the potential of our broader product portfolio across multiple international markets. This agreement validates our pharmaceutical manufacturing expertise and positions us well for growth.”

Aurora Cannabis also highlighted the manufacturing focus of the collaboration, particularly in strengthening supply chains. Alex Miller, Executive Vice President, Operations & Supply Chain at Aurora, said: “As a global leader in medical cannabis, we’re focused on building a resilient, high-quality supply chain across key international markets. BLS brings strong GMP-manufacturing capabilities that complement our scale, regulatory scrutiny and commitment to delivering high quality medical cannabis products to patients.”

According to the release, the agreement has an initial 12-month rolling term with automatic renewal, and can be terminated with six months’ notice. Both companies have begun onboarding additional product lines, with discussions ongoing regarding further manufacturing and supply opportunities across the same international markets.

Bioxyne said the agreement reflects its progression from an Australian-based manufacturer to a participant in global pharmaceutical cannabis supply, while Aurora framed the partnership as part of its broader effort to maintain consistent product quality and supply across regulated markets.

Article by Australian Manufacturing: https://www.australianmanufacturing.com.au/manufacturing-deal-signed-between-bioxyne-and-aurora-cannabis-for-medicinal-products/

In this episode, we sit down with Sam Watson, managing director of Bioxyne (BXN:ASX), to unpack how the company is positioning itself at the intersection of medicinal cannabis, psychedelics, and precision medicine. We dive into the regulatory landscape across the UK and Australia, breaking down how prescribing works and why navigating compliance is critical to success. A key focus is GMP certification, and how maintaining pharmaceutical-grade standards builds trust and creates a competitive edge. We also explore Bioxyne’s strategy of manufacturing finished products, from inhalable flower to fast-growing formats like pastilles, and how they’ve carved out a strong position in the Australian market. Beyond cannabis, the conversation touches on emerging therapies like psilocybin and MDMA, and the growing opportunity to treat conditions like depression and PTSD. Finally, Sam shares Bioxyne’s unique approach to commercialising investigational medicines earlier to accelerate growth while managing risk. This is one of the fastest-growing sectors in healthcare — and Bioxyne is one of the few ASX-listed names that’s doing it profitably.

Watch Sam’s interview via Vantage Point here: https://www.youtube.com/watch?v=PNFQAydFIDo

Podcast: ASX Briefs – Sam Watson Interview

A 149% revenue surge, first‑to‑market GMP MDMA in Australia, and a plan to scale faster than demand—Sam Watson, CEO of Bioxyne, joins us to unpack how a focused manufacturer turns emerging therapeutics into real‑world access. We dig into the mechanics behind record growth, the patient need driving MDMA and psilocybin uptake, and why replicable GMP capacity across Australia, the UK, and Europe is Bioxyne’s not‑so‑secret weapon.

Sam explains how medicinal cannabis remains the commercial engine while psychedelic therapeutics validate a long‑term bet on treatment‑resistant depression and PTSD. With authorised prescriber pathways opening and imports giving way to local GMP supply, clinics gain reliable access and patients get consistent, pharmacy‑grade dosing. We talk through the numbers—upgraded adjusted EBITDA guidance to 16–19 million—and the process upgrades that power it: automation, digitised quality systems, and operating leverage as volumes climb.

We also map the international play. Germany leads as a prescriber‑led, pharmacy‑dispensed market where cannabis flower dominates and Bioxyne targets five to ten tons over the next year through strong local partnerships. The UK mirrors Australia’s earlier stage, making it ripe for a copy‑and‑paste facility to relieve supply bottlenecks. Finally, Sam outlines how rapid clean room buildouts, short payback cycles, and white‑label reliability for 300+ brands create a durable moat: faster turnaround, fewer stockouts, and scalable quality at GMP standards.

Listen to the ASX Briefs podcast here: https://open.spotify.com/episode/1sSfcx8XvcKW16VpPOYV3c?si=pdizuRY-TQi8ftu0T9RmgA&nd=1&dlsi=c51597bc07e4492a

• Bioxyne is revelling in its status as one of only a few profitable ASX medical cannabis stocks
• Regulators are tackling the ‘wild west’ elements of the Australian market, but it’s still tipped to grow to more than $1 billion a year
• In a sign of the times, Little Green Pharma proposes to merge with the unlisted Cannatrek to create a sector giant

Bioxyne (ASX:BXN) founder and CEO Sam Watson is replete with praise for Australia’s medicinal cannabis regimen – but the wacky labelling needs to go.

“I have seen some crazy labelling he says,” he says. “Aliens and rastas in bright colours and things like that.”

Snoop Dogg has his own label, naturally.

Bioxyne doesn’t grow its own stuff, but ‘white labels’ product for dozens of other suppliers.

“Sometimes we look at the proposed label and say ‘we don’t want to make that product’,” Watson says.

“It’s more like recreational cannabis and not in the spirit of where the industry should be going.”

Sure enough, a Therapeutic Goods Administration (TGA) crackdown means self-respecting doctors no longer will have to prescribe ‘donkey breath’ or THC-infused ‘peanut butter balls’ for chronic pain.

Watson says the Australian regimen is meant to be a special access scheme, to enable patients not responding to traditional medicine to access the unapproved products.

“But sometimes there have been overly zealous prescribers and that’s where we need to focus and tighten the belt.”

Meanwhile, the sector is due for much-needed consolidation with the proposed merger of the ASX listed Little Green Pharma (ASX:LGP) and the unlisted Cannatrek.

Read the full Article by Stockhead  here: https://stockhead.com.au/health/biocurious-for-bioxyne-chief-sam-watson-pot-stock-success-is-more-than-a-funky-labelbiocurious-for-bioxyne-chief-sam-watson-pot-stock-success-is-more-than-a-funky-label/

Bioxyne lifts FY26 EBITDA guidance to AUD16.5-19m after record H1 FY2026 with AUD31.3m revenue (+149% YoY); expands capacity, enters UK/Germany/LATAM.

Key points

• Record H1 revenue and substantial EBITDA guidance upgrade.
• Operational milestones achieved: expanded GMP capacity and first Australian-made MDMA capsules.
• International growth strategy advancing with new markets entered and UK facility development.

Bioxyne (ASX: BXN) has significantly upgraded its  EBITDA guidance to AUD16.5-19 million on the back of record H1 FY2026 results, reporting revenue of AUD31.3 million—a substantial 149% increase year-on-year.

The company reported adjusted EBITDA of AUD8.3 million and a net profit after tax (NPAT) of AUD7.3 million.

Bioxyne additionally announced multiple strategic developments including capacity expansions and international market entries.

FY26 revenue guidance remains unchanged, projected to be between AUD65 million and AUD75 million.

The improvements in H1 margins contributed to this revised EBITDA outlook, a factor the company will focus on maintaining.

Expanded Manufacturing Capacity and MDMA Milestone

Bioxyne continued to scale its Good Manufacturing Practice (GMP) capabilities, successfully increasing its GMP clean room capacity by 100% and its storage capacity by 200%.

This expansion supports higher production volumes for its specialised product lines.

A major operational milestone was achieved with the successful production of the first Australian-made GMP-certified MDMA capsules.

This development is critical for Bioxyne’s psychedelic product pipeline.

The company states its total revenue capacity for finished products now exceeds AUD250 million per year, with its Australian facility capable of producing up to 6 million MDMA pastilles per month.

International Expansion Gains Traction

Bioxyne made significant strides in its international market penetration, entering new territories including the UK, Germany, and LATAM.

Initial shipments to Germany alone generated AUD2.7 million in revenue during H1 FY26.

To further bolster its global footprint and enhance access to European capital, the company completed a dual listing on the Frankfurt Stock Exchange (PR8.F) on October 13, 2025.

Furthermore, development of a UK GMP manufacturing facility in the Scottish Borders is underway, with construction starting in February 2026 and completion targeted for June 2026.

This facility is supported by £0.848 million in non-dilutive funding from South of Scotland Enterprise, with licensing for the UK facility targeted for December 2026.

Strong Financial Position and Funding

At the end of H1 FY2026, Bioxyne reported a cash on hand balance of AUD7.6 million.

The company’s net assets stood at AUD20.0 million, with total assets of AUD34.6 million and total liabilities of AUD14.5 million.

To meet anticipated demand, inventories increased to AUD11.7 million, and trade receivables were AUD5.8 million.

This strategic inventory build contributed to a negative operating cash flow of AUD1.29 million during the H1 FY26 period.

The previously mentioned £0.848 million non-dilutive funding for the UK GMP site provides additional financial support for its growth initiatives.

Article by SmallCaps – https://smallcaps.com.au/article/bioxyne-bxn-boosts-fy26-outlook-on-strong-performance-and-international-growth

Medicinal cannabis manufacturer Bioxyne has received its first order of GMP-manufactured psilocybin capsules for investigational use in treatment-resistant depression.

The order will see Bioxyne subsidiary Breathe Life Sciences (BLS) supply 250 doses to authorised prescribers in Queensland and Western Australia to treat approximately 60 patients over the next 12 months.

The capsules will also be used for exploratory research into other mental health conditions including anxiety disorders, substance use disorder and PTSD.

Bioxyne chief executive Sam Watson said BLS was “translating its psychedelic manufacturing capabilities into early commercial results and positive patient outcomes”.

“For Bioxyne, these initial supply agreements reflect disciplined execution at the outset of a multi-billion dollar opportunity with the potential to meaningfully improve quality of life for millions of people,” he said.

Article by Cannabiz – https://www.cannabiz.com.au/news-in-brief-bioxyne-receives-first-psilocybin-order/ 

Bioxyne has plenty of ‘shroom to move after first psilocybin sale.

A first mover in making psychedelic medications, Bioxyne (ASX:BXN) has reported its first local order for its psilocybin capsules.

The company is the only compliant local manufacturer of this substance – a.k.a. ‘magic mushrooms’ – which is being trialed for treatment-resistant depression.

Psilocybin also could be relevant for anxiety, substance abuse and post-traumatic stress disorder.

Bioxyne has supplied the capsules to clinicians in Queensland and WA, who work via the Therapeutic Goods Administration’s Authorised Prescriber Scheme.

The order is for 250 doses: enough to treat around 60 patients for the next 12 months.

“This represents only a small fraction of Australia’s estimated addressable market of approximately 300,000 patients living with treatment-resistant depression,” Bioxyne says.

“The company is prepared to scale manufacturing and supply significantly over the next 12 months to meet anticipated demand across Australia.”

Earlier, Bioxyne shipped its first order for MDMA – ‘Molly’ – which it also manufactures.

For the time being, the company derives most of its revenue from making and selling medical cannabis, both here and in Europe and the UK.

Article by Stockhead – https://stockhead.com.au/health/health-check-csl-loses-16-billion-of-value-in-a-bloody-results-horror-show/

ASX biotechs are serving up champion performances amid the odd fault or two, as reflected in today’s crop of quarterly reports.

• Life science companies are flooding the bourse with quarterly reports
• Many of them are hitting winners with trial updates and revenue upgrades
• Bioxyne served up record revenue with its dual medical cannabis and psychedelics strategy

Bioxyne is on a high

We’ll start with Bioxyne (ASX:BXN), which is hitting some solid aces with its dual medicinal cannabis and psychedelics strategy.

Unlike most of its peers, Bioxyne is solidly revenue-generating and profitable.

Bioxyne reported record December quarter revenue of $17.2 million, 11% higher year on year, with $2.5 million of positive cash flow.

The company reports “sustained growth” for its local Breathe Life Sciences (BLS) arm.

BLS supplies cannabis flower, oils, vapes and pastilles.

If these delivery mechanisms don’t cut it, the company has also launched a third-party inhalation device.

Bioxyne largely is focused on Europe, notably Germany, which “de-narcotised” medical cannabis in 2024.

“Germany is the largest and fastest growing legal cannabis market in Europe, projected to surpass €1 billion ($1.8 billion) in sales in 2026,” the company says.

On the psychedelics side, locally Bioxyne released the first Australian-made MDMA (‘Molly’) capsules. These supply clinical trials and authorised prescribers in Queensland.

The company also supplied pills to Victoria’s Eastern Health, for a treatment-resistant post-traumatic stress disorder trial.

CEO Sam Watson says the company is “firmly on track” to deliver on its current full-year guidance of $65–75 million of revenue and $11.5–13.5m in underlying earnings.

Bioxyne dual listed on the Frankfurt Stock Exchange last October, “enhancing liquidity and access for European investors”.

Article by Stockhead: https://stockhead.com.au/health/health-check-biotech-quarterlies-serve-up-sizzling-aces-and-only-a-few-unforced-errors/

Brisbane manufacturer Bioxyne delivered record quarterly revenue of A$17.2 million in Q2 FY26, a 21% increase on Q1 and a 112% life on the previous corresponding year.

Cash receipts reached a record $18.4m, up 149% on Q2 FY25, while net cash from operating activities was positive at $2.5m.

Article by Cannabiz  – https://www.cannabiz.com.au/bioxyne-hits-record-quarterly-revenue/